Tepylute’s liquid formulation reportedly eliminates the need for complex and time-consuming reconstitution, providing consistent dosing accuracy and allowing for timely preparation.
FDA Approves New Drug Application for Shorla Oncology’s Tepylute, a Pre-Diluted Formulation for the Treatment of Breast and Ovarian Cancer
Leave a comment
